The company operates across various sectors, addressing regulatory issues, holding patents, and engaging in industry competition, but specific financial or customer data is not provided.

# Company Summary

The provided excerpt contains sections from an annual or quarterly report but does not include specific details such as the company's name, number of customers, total employees, revenue, or income. Instead, it outlines the structure of the report, indicating the company's areas of focus:

- **Business Overview (Part I, Item 1):**
  - **Regulatory Matters:** The company addresses regulatory issues impacting its operations.
  - **Patents and Proprietary Rights:** It holds patents and proprietary assets crucial to its business.
  - **Competition:** The report discusses competitive dynamics in its industry.
  - **Employees:** Employee-related information is included, though specific numbers are not provided.
  
- **Risk Factors (Item 1A):**
  - Identifies risks affecting the company's operations and financial health.

- **Unresolved Staff Comments (Item 1A.1):**
  - Mentions any unresolved communications or comments from regulatory staff.

- **Properties (Item 1B):**
  - Describes physical assets or property holdings.

- **Legal Proceedings (Item 2):**
  - Details ongoing or past legal issues.

- **Mine Safety Disclosures (Item 3):**
  - Pertains to safety disclosures related to mining activities.

**Note:** The excerpt does not provide specific quantitative data such as the total number of customers, employees, revenue, or net income. It only outlines the topics covered within the report.

Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for orphan oncology indications and rare pediatric cancers using innovative technologies.

## Oncotelic Therapeutics, Inc. Overview

### Company Background
- **Founded**: 1988 as OXiGENE, Inc.
- **Reincorporated**: Delaware, 1992
- **Name Changes**: Mateon Therapeutics, Inc. in 2016; Oncotelic Therapeutics, Inc. in November 2020.
- **Headquarters**: Agoura Hills, California, USA.
- **Website**: [oncotelic.com](http://www.oncotelic.com)

### Business Focus
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the research and development of drugs for treating orphan oncology indications, particularly rare pediatric cancers. The company develops:
- **Antisense and small molecule injectable drugs for various cancers**.
- **AI technologies** for clinical development and manufacturing processes.
- **Other indications** including Parkinson’s Disease, erectile dysfunction, and female sexual dysfunction.

### Product Candidates
1. **OT-101**: An antisense against TGF-β2 for the treatment of cancers and viral infections, including COVID-19.
2. **AL-101**: An intranasal apomorphine asset for Parkinson’s Disease, erectile dysfunction, and female sexual dysfunction.
3. **CA4P**: A vascular disrupting agent for solid tumors, including pediatric melanoma and other cancers.
4. **OXi4503**: A treatment for acute myeloid leukemia and myelodysplastic syndromes.

### Organizational Structure and Operations
- **Subsidiaries**: 
  - Oncotelic, Inc. (Delaware)
  - PointR Data, Inc. (Delaware)
  - Pet2DAO, Inc. (for animal health products)
  - EdgePoint AI, Inc.

- **Partnerships**: Joint venture with GMP Biotechnology Limited and Dragon Overseas Capital for collaborative drug development.

### Financial Overview
- **Employees**: 22 full-time employees and consultants as of December 31, 2023.
- **Net Revenue**: Currently, the company has no source of product revenue, with future revenue largely uncertain.
- **Net Loss**: Approximately $7.9 million in 2023, with an accumulated deficit of approximately $33.5 million.

### Goals and Market Strategy
- **Development Goals**: 
  - Continue advancing clinical trials for multiple oncology and therapeutic indications.
  - Exploring strategic alliances and licensing arrangements for product portfolio.
  - Potential IPO of the joint venture, GMP Bio, for capital resources.
  
- **Market Position**: The company is positioning itself for potential revenue from its candidates following clinical success and regulatory approvals, leaning into its Rare Pediatric Designation for certain therapies to enhance their marketability.

### Risks and Challenges
- **Funding**: The company is under significant capital constraints and is seeking funding to continue operations. This uncertainty creates substantial risks regarding ongoing clinical trials and business viability.
- **Regulatory Compliance**: The company must adhere to stringent FDA regulations for its product candidates, which may affect development timelines and costs.

### Unique Aspects
Oncotelic's dual approach focuses on rare pediatric diseases and integrating AI into clinical development and manufacturing processes, which may enhance efficiencies and outcomes in their therapeutics’ potential market success.

Oncotelic Therapeutics, Inc.

10-K / April 15, 2025

10-K / April 12, 2024

10-K / April 15, 2025

Company Summary